Non-pharmaceutical treatment combats recurring Clostridium Difficile infections
Transplanting human donor fecal microbiota into the colon of a patient infected with Clostridiodes difficile (C. diff) may be the best treatment for those not helped by C. diff targeted antibiotics, according to an article in the Journal of the American Osteopathic Association.
C. diff is the most common healthcare-acquired infection in the United States. It affects nearly half a million patients each year and becomes a recurring infection for nearly a third of them. If untreated, C. diff can lead to sepsis and death.
“Twenty five years ago C. diff infections were easier to manage and often resolved with discontinuation of the initiating antibiotic,” says Robert Orenstein, DO, an infectious disease specialist at Mayo Clinic and lead author on this article. “However, these infections have become increasingly common and pernicious.”
The standard and FDA-approved treatment for C. diff is a course of oral vancomycin, an antibiotic. However, even the medications used to eliminate C. diff can perpetuate the infection by killing off beneficial microbes. Newer antibiotics that more specifically target C. diff have been developed but they can be prohibitively expensive, according to Dr. Orenstein.
“Think of your gut as a forest and C. diff as a weed,” says Dr. Orenstein. “In a thriving forest, weeds barely get a foothold. But if you burn the forest down, the weeds are going to flourish.”
Unlike antibiotics, which are destructive by definition, fecal transplants or microbial replacement therapies, repopulate the gut with a diverse group of microbes that may block the C. diff‘s spore from germinating and propagating disease via its toxins. Transplants have several delivery methods, including enemas, capsules and direct instillation, to replace the diverse flora that maintain health and improve metabolism.
Currently, there are no FDA-approved fecal transplant products and performing fecal transplants is considered an investigational procedure. Dr. Orenstein notes there are several companies with products in Phase 3 clinical trials that could come to market as early as 2020. For this reason he strongly urges healthcare providers to refer patients with recurrent C. diff for these trials rather than for fecal transplants. In the meantime, the FDA reserves fecal transplants for patients who have experienced a second recurrence (third episode) of C. diff infection.
C. diff is common in healthcare settings and public spaces and rarely causes problems in people with healthy gut microbiota and immune systems, according to researchers. However, people who are already ill and taking antibiotics, chemotherapy, or proton pump inhibitors–which all greatly disrupt the gut ecosystem–are at risk. Elderly patients are especially vulnerable.
Dr. Orenstein expects the new treatment options will improve outcomes but says physicians need to assume greater responsibility for prevention.
“One of the most effective things physicians can do is become more responsible with antibiotic prescriptions,” says Dr. Orenstein. “That means only prescribing when they are clearly indicated, not for colds or viral sinus infections. We also must be especially judicious with elderly patients.”
The Latest on: Fecal transplants
via Google News
The Latest on: Fecal transplants
- Neonatal antibiotic exposure impairs child growth during the first six years of life by perturbing intestinal microbial colonizationon January 25, 2021 at 4:00 pm
In this study, Omry Koren, Samuli Rautava and colleagues report a sex-specific association between neonatal antibiotic exposure and weight and height gain during the first six years of life and ...
- Naturalizing mouse models for immunologyon January 24, 2021 at 4:00 pm
Animal models provide invaluable insights into the functioning of the immune system; however, they have their limitations. In a Perspective, Andrea Graham argues that using a more naturalized biotic ...
- Woman Becomes Obese After Fecal Transplant From Overweight Donoron January 15, 2021 at 10:30 am
While they may sound totally disgusting, fecal transplants are emerging as a promising treatment for a variety of gastrointestinal diseases, in particular ...
- Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantationon January 13, 2021 at 4:00 pm
The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene ...
- Microbiome transplants can reprogram immune system to attack tumorson January 13, 2021 at 7:39 am
The researchers performed fecal microbiota transplantation (FMT) on 10 terminally ill patients with metastatic melanoma who had not responded to immunotherapy and had exhausted all other existing ...
- Fecal Transplants Safe Long Term for Recurrent C. Diffon January 12, 2021 at 2:00 pm
More evidence has emerged for fecal microbiota transplantation (FMT) as a safe option for treating recurrent Clostridioides difficile infection (CDI), according to a survey-based study.
- Poor gut health connected to severe COVID-19, new review showson January 12, 2021 at 3:03 am
Eating more fiber, he said, may lower a person's risk of serious disease. And fecal microbiota transplantation might be a treatment worth considering for patients with the worst cases of COVID-19.
- Medscape Medical Newson January 10, 2021 at 4:00 pm
October 20, 2014 Cure Rates Remain High With Fecal Transplant for C difficile High and sustained cure rates continue to be reported after fecal microbiota transplant for patients with recurrent ...
- Alteration of the Intestinal Microbiomeon January 1, 2021 at 4:00 pm
Although the most common application for FMT has been in the setting of recurrent CDI, there is ongoing research to assess benefit in other gastrointestinal diseases. These include inflammatory ...
- TOP GASTROINTESTINAL DOCTORS BORODY AND HAZAN RELEASE HUMOROUS, EASY TO DIGEST BOOK 'LET'S TALK SH!T'on December 28, 2020 at 2:54 pm
t' addressing disease, digestion and fecal transplants. An estimated 188.9 million adult Americans (74.02% of the population) make New Year's resolutions to better themselves each year ...
via Bing News